regardless of promising clinical evidence, copyright's Vyndamax, a therapy for hereditary transthyretin-mediated amyloidosis (hATTR), is encountering significant resistance from pharmacy benefit managers. Such companies are often creating barriers to coverage, such as significant cost criteria and approval processes that hinder patient opportunity.